Are you Dr. Archdeacon?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 62 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
101 Manning Dr
Chapel Hill, NC 27599Phone+1 919-966-4996Fax+1 919-843-5515- Is this information wrong?
Summary
- Dr. Patrick Archdeacon, MD is a nephrologist in Chapel Hill, North Carolina. He is currently licensed to practice medicine in North Carolina and Maryland.
Education & Training
University of North Carolina HospitalsFellowship, Nephrology, 2005 - 2007
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
Columbia University Vagelos College of Physicians and SurgeonsClass of 2001
Certifications & Licensure
MD State Medical License 2017 - 2024
NC State Medical License 2006 - 2019- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 13 citationsFDA-Catalyst—Using FDA’s Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial:Noelle M. Cocoros, Sean D. Pokorney, Kevin Haynes, Crystal Garcia, Hussein R. Al-Khalidi, Sana M. Al-Khatib, Patrick Archdeacon, Jennifer C. Goldsack, Thomas Harkins, ...> ;Clinical Trials. 2019 Feb 1
- 5 citationsEvaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug-outcome associations: The case of clindamycin and Clos...Ryan M. Carnahan, Jennifer L. Kuntz, Shirley V. Wang, Candace C. Fuller, Joshua J. Gagne, Charles E. Leonard, Sean Hennessy, Tamra Meyer, Patrick Archdeacon, Chih-Ying...> ;Pharmacoepidemiology and Drug Safety. 2018 Jul 1
- 36 citationsRecommendations for data monitoring committees from the Clinical Trials Transformation Initiative.Karim A. Calis, Patrick Archdeacon, Raymond P. Bain, David L. DeMets, Miriam Donohue, M. Khair ElZarrad, Annemarie Forrest, John McEachern, Michael J. Pencina, Jane Pe...> ;Clinical Trials. 2017 May 13
- Join now to see all
Press Mentions
New Drug Watch: A Validation of the ‘Twincretin’ Approach to Type 2 DiabetesJune 24th, 2022- FDA Approves Novel, Dual-Targeted Treatment for Type 2 DiabetesMay 13th, 2022
- FDA Approves New Lilly Diabetes TreatmentMay 13th, 2022
- Join now to see all
